Form 10-Q · Quarterly report
DuPont 10-Q, filed Aug 4, 2026
- Filed
- CIK
- 0001666700
- Accession no.
- 0001666700-26-000053
Summary
DuPont reported net sales of $1.8 billion for the quarter ended June 30, 2026, up 4 percent from $1.7 billion a year earlier on a 4 percent rise in organic sales. The company said it began receiving refunds of tariffs the U.S. Supreme Court invalidated in February 2026, a ruling still subject to further appeal, and that it shares 44 percent of pre-November 2025 tariff refunds with Qnity under their tax matters agreement.
Key points
- DuPont completed the sale of its Aramids business to Arclin, a TJC LP portfolio company, on April 1, 2026 for about $1.2 billion in pre-tax cash plus a $300 million note receivable and a $325 million equity interest.
- A 1-for-3 reverse stock split of DuPont common stock became effective June 24, 2026.
- DuPont declared a third-quarter 2026 dividend of $0.60 per share, payable September 15, 2026 to holders of record August 31, 2026.
- Second-quarter R&D expenses fell to $42 million from $53 million a year earlier.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT'S DISCUSSION OVERVIEW DuPont is a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. The Company is committed to helping customers advance their technology pipelines and provide solutions that address their unique challenges. From delivering clean water to enabling medical packaging solutions which enhance safety and performance, DuPont's innovations power the essential products and technologies people rely on every day. As of June 30, 2026, the Company had $2.9 billion of working capital and approximately $1.7 billion in cash and cash equivalents. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.